Novo Nordisk CEO says CVS breakup has no material impact on the weight-loss drug giant
Novo Nordisk CEO Mike Doustdar said CVS Health’s planned breakup is unlikely to materially affect sales of its weight-loss drugs, though Novo will need to negotiate separately with the two resulting companies. CVS plans to separate its… retail pharmacy business from its insurance, pharmacy-benefit management, and primary-care operations by the first half of 2028.